AHL Investment Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$2.55M Buy
100,112
+5,410
+6% +$134K 1.74% 22
2025
Q2
$2.3M Buy
94,702
+2,920
+3% +$68.1K 1.53% 25
2025
Q1
$2.33M Buy
91,782
+6,345
+7% +$166K 1.6% 24
2024
Q4
$2.27M Buy
85,437
+550
+0.6% +$14.9K 1.59% 22
2024
Q3
$2.46M Buy
84,887
+10,784
+15% +$315K 1.69% 22
2024
Q2
$2.07M Buy
74,103
+936
+1% +$25.8K 1.52% 24
2024
Q1
$2.03M Buy
73,167
+4,440
+6% +$123K 1.56% 27
2023
Q4
$1.98M Hold
68,727
1.62% 26
2023
Q3
$2.28M Buy
68,727
+5,971
+10% +$211K 2.03% 19
2023
Q2
$2.3M Buy
62,756
+10,407
+20% +$405K 2.05% 18
2023
Q1
$2.14M Buy
52,349
+34
+0.1% +$1.47K 1.97% 17
2022
Q4
$2.68M Sell
52,315
-1,841
-3% -$88.3K 2.49% 14
2022
Q3
$2.37M Buy
54,156
+5,205
+11% +$253K 2.44% 15
2022
Q2
$2.57M Buy
48,951
+445
+0.9% +$22.7K 2.58% 14
2022
Q1
$2.51M Sell
48,506
-720
-1% -$37.4K 2.3% 16
2021
Q4
$2.91M Buy
+49,226
New +$2.44M 2.65% 13

Other funds holding PFE

AHL Investment Management's PFE Position: Q3 2025 in Review

AHL Investment Management increased its Pfizer (PFE) stake by 5.7% in Q3 2025, buying an estimated $134K and bringing the position to 100,112 shares worth $2.55M. The position accounts for 1.74% of the portfolio, ranked #22.

AHL Investment Management first reported a position in PFE in Q4 2021 and has held it in 16 quarters since. The position peaked at $2.91M in Q4 2021. 2,812 funds tracked by Wall St. Rank hold PFE as of Q3 2025.

  • AHL Investment Management held 100,112 shares of Pfizer worth $2.55M as of Q3 2025.
  • AHL Investment Management bought 5,410 Pfizer shares in Q3 2025, an estimated $134K.
  • Pfizer made up 1.74% of AHL Investment Management's portfolio in Q3 2025, its #22 holding.
  • AHL Investment Management first reported a position in Pfizer in Q4 2021 and has held it in 16 quarters since.
  • AHL Investment Management's Pfizer position peaked at $2.91M in Q4 2021.
  • 2,812 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.

Based on AHL Investment Management's 13F filing for Q3 2025, filed 2 Oct 2025.